NCT03899415 is a Phase 1 clinical trial of TCR redirected T cells in Hepatocellular Carcinoma, sponsored by Beijing 302 Hospital.

Who is sponsoring NCT03899415?

NCT03899415 is sponsored by Beijing 302 Hospital.

What drugs are being tested in NCT03899415?

Interventions in NCT03899415: TCR redirected T cells.

What condition does NCT03899415 study?

NCT03899415 studies Hepatocellular Carcinoma.

Is NCT03899415 still recruiting?

NCT03899415 is currently status unknown. Last updated 10 April 2019.

Last reviewed 2019-04-10 · How we verify

NCT03899415

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TCR-Redirected T Cells Therapy in Patient With HBV Related HCC

Status unknown Phase 1 Last updated 10 April 2019

What this trial tests

Phase 1 trial testing TCR redirected T cells in Hepatocellular Carcinoma in 10 participants. Status unknown.

Timeline

20 April 2019

Primary endpoint
1 June 2022

1 June 2024

Quick facts

Lead sponsor	Beijing 302 Hospital
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	20 April 2019
Primary completion	1 June 2022
Estimated completion	1 June 2024
Sites	1 location across China

Drugs / interventions tested

TCR redirected T cells — full drug profile →

Conditions studied

Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →

Sponsor

Beijing 302 Hospital

Who can join

Adults 18 to 70, any sex, with Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single center. single arm, open-label study to determine the safety and clinical benefit of TCR-redirected T cell therapy in patient with HBV related HCC post hepatectomy or radiofrequency ablation.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Advances in immunotherapy for hepatocellular carcinoma.
Sangro B, Sarobe P, Hervás-Stubbs S, Melero I. · · 2021 · cited 1002× · PMID 33850328 · DOI 10.1038/s41575-021-00438-0
T cells in health and disease.
Sun L, Su Y, Jiao A, Wang X, et al · · 2023 · cited 717× · PMID 37332039 · DOI 10.1038/s41392-023-01471-y
TCR-engineered T cell therapy in solid tumors: State of the art and perspectives.
Baulu E, Gardet C, Chuvin N, Depil S. · · 2023 · cited 283× · PMID 36791198 · DOI 10.1126/sciadv.adf3700
Hepatocellular carcinoma: signaling pathways and therapeutic advances.
Zheng J, Wang S, Xia L, Sun Z, et al · · 2025 · cited 142× · PMID 39915447 · DOI 10.1038/s41392-024-02075-w
Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives.
Shen KY, Zhu Y, Xie SZ, Qin LX. · · 2024 · cited 140× · PMID 38679698 · DOI 10.1186/s13045-024-01549-2
Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects.
Liu Z, Liu X, Liang J, Liu Y, et al · · 2021 · cited 109× · PMID 34675942 · DOI 10.3389/fimmu.2021.765101
Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells: results of dose escalation, phase I trial.
Meng F, Zhao J, Tan AT, Hu W, et al · · 2021 · cited 86× · PMID 34850325 · DOI 10.1007/s12072-021-10250-2
Liver Cancer Immunity.
Ilyas SI, Wang J, El-Khoueiry AB. · · 2021 · cited 81× · PMID 32516437 · DOI 10.1002/hep.31416

Verify or expand the search:

Other recruiting trials for Hepatocellular Carcinoma

Currently open trials in the same condition.

NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma · Phase 2 · recruiting
NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting

Other Beijing 302 Hospital trials

Trials by the same sponsor.

NCT07514832 — VA-CIG Regimen for Previously Untreated Acute Myeloid Leukemia: A Multicenter Prospective Single-Arm Trial · Phase 2 · recruiting
NCT07297173 — Phase 1 Study of Chemotherapy Plus HLA-mismatched GPBMC Infusion Bridging to Allo-HSCT for R/R Leukemia · Phase 1 · recruiting
NCT06556862 — Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor · Phase 2 · not yet recruiting
NCT07106658 — TEAS for Variceal Bleeding Endoscopy in Cirrhosis · NA · completed
NCT06926647 — A Real-World Study of Antiviral Therapy in Children With Chronic Hepatitis B · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03899415 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Beijing 302 Hospital
Last refreshed: 10 April 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03899415.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing